The best outcome for patients with Ph chromosome-negative ALL (Ph( À ) ALL) can be obtained by HLA-matched related donor (mRD) allogeneic hematopoietic cell transplantation (allo-HCT) in first CR. However, only 30% of patients have a mRD. Three alternative sources, unrelated donor (URD), cord blood, and haploidentical related donor (haplo-RD), are available. URD allo-HCT is an old-established alternative source, and recent data have shown that URD allo-HCT can result in OS comparable with that with mRD allo-HCT for patients with Ph( À ) ALL in first CR (OS at 4 years: mRD 65% vs URD 62%). Unrelated cord blood transplantation can also be indicated for patients with Ph( À ) ALL in first CR (OS at 4 years: 57%), especially for young patients without an HLAmatched URD or patients who are in urgent need for allo-HCT. Limited data for haplo-RD allo-HCT for ALL showed utility in CR (OS at 3 years: up to 65%) but a survival rate of only 5-7% in non-CR. As there are no confirmed data about the utility of allo-HCT from an alternative source for adolescent and young adults who are eligible for pediatric protocols or for elderly patients with reducedintensity conditioning. Further investigation, including investigation of minimal residual disease detection, may reveal subgroups of patients who can receive benefits from allo-HCT. Selection of the best source based on the patient status and appropriate timing is warranted.
INTRODUCTION
The prognosis of adult ALL is still unsatisfactory; long-term survival has been achieved in only about 30-40% of patients despite a considerably high CR rate (78-93% in major clinical trials). [1] [2] [3] [4] [5] [6] [7] [8] Allogeneic hematopoietic cell transplantation (allo-HCT) is the most potent post-consolidation therapy and curative option for ALL. Only 30% of patients have an HLA-matched related donor (mRD), and the majority of patients who need allo-HCT will therefore require alternative hematopoietic cell sources. [9] [10] [11] In this review, we discuss allo-HCT from alternative donors for adult ALL. It may be better to treat Ph chromosome-positive (Ph( þ )) ALL and Ph chromosome-negative ALL (Ph( À ) ALL) as different diseases, as their treatment would differ in the era of tyrosine kinase inhibitors. 12 Therefore, we mainly analyzed data for Ph( À ) ALL patients whenever possible.
Prognostic factors of ALL Allo-HCT should be performed only when its therapeutic benefits would outweigh the expected complications, such as toxicity of conditioning and GVHD, arising from donor immune response. Therefore, it is crucial to determine the high-risk group for ALL chemotherapy. The definition of high-risk ALL differs depending on the study group; the age at diagnosis, white blood cell count at diagnosis, cytogenetic abnormalities, and sometimes the intervals to achieve CR are considered to be risk factors (Table 1) . Recently, minimal residual disease (MRD) has been recognized as a risk factor for relapse. [13] [14] [15] [16] [17] MRD can be evaluated by using either multichannel flow cytometry or RQ-PCR, which are applicable to 70-80% of all the patients. 18 It should be noted that these risk factors have been established to stratify chemotherapy outcomes, and therefore it is a separate issue whether they can also be used to stratify allo-HCT outcomes. The outcomes of chemotherapy for Ph( À ) ALL are summarized in Table 2 . Although CR rate of ALL chemotherapy is high (up to 90%), long-term survival is unsatisfactory. This means that many patients who achieve the first CR will relapse during/after consolidation or maintenance chemotherapy. Once relapsed, the outcome will be dismal.
allo-HCT for patients with Ph( À ) ALL in the first CR (Table 3 ). The largest genetic randomization (donor vs no donor comparison) for adult Ph( À ) ALL in the first CR was reported from UKALL XII/ECOG 2993. 22 As OS was significantly better among patients with a mRD (53% at 5 years, n ¼ 443) than for those without a mRD (45% at 5 years, n ¼ 588) (P ¼ 0.01), it was concluded that use of mRD allo-HCT should be part of the most potent anti-leukemic strategy for patients with Ph( À ) ALL in the first CR. In a Japanese study, the rates of OS, relapse, and non-relapse mortality (NRM) among 310 patients were comparable with those in UKALL XII/ECOG 2993. 23 Survival analyses such as genetic randomization are usually concerned about survival data alone (that is, alive or dead), and quality-of-life factors such as chronic GVHD cannot be fully evaluated by such analyses. A decision analysis has been proposed as a new method for validating the indication of allo-HCT. 24 Even with quality-of-life adjustments in such an analysis, long-term survival would be better in patients who underwent allo-HCT in the first CR than in those who underwent chemotherapy alone.
UNRELATED DONOR (URD) ALLO-HCT FOR ADULT PH( À ) ALL IN THE FIRST CR URD is the most prevalent alternative source for patients without a mRD ( Table 3 ). The outcomes of 169 adult Ph( À ) ALL patients who underwent URD allo-HCT in the first CR were reported from the Center for International Blood and Marrow Transplant Research (CIBMTR). 25 Although relapse rates were as low as 20% at 5 years, OS remained at 39% at 5 years due to high NRM (42% at 5 years). In a Japanese study, the rates of OS, relapse, and NRM at 4 years among 331 patients who underwent URD allo-HCT were 62, 22 and 27%, respectively, which were better than those reported by CIBMTR. 23 These differences in NRM could be explained by the lower incidence of acute GVHD, which may have resulted from the genetic homogeneity of the Japanese population. 26, 27 HLA-mismatch and X10 months from the time of diagnosis to allo-HCT were associated with NRM, indicating that a better outcome could be achieved by performing allo-HCT at a more appropriate time and by using better HLA matches.
Comparison of mRD and URD allo-HCTs in the first CR There is controversy over whether performing URD allo-HCT for patients with Ph( À ) ALL in the first CR is advantageous when no mRD is available. Although OS rates for patients who underwent mRD and URD allo-HCTs in the large Japanese retrospective study described above were comparable, 23 relapse rates were higher in patients who underwent mRD allo-HCT, whereas NRM rates were higher in patients who underwent URD allo-HCT. As both the CIBMTR and the Japanese studies were retrospective studies, selection biases from different backgrounds of patients who underwent mRD and URD allo-HCTs could not be eliminated.
Time-censoring effect As a longer interval from diagnosis to URD allo-HCT eliminates the effect of patients who die during that period, it creates a bias that seemingly improves the outcome of URD allo-HCT. A correction for this time-censoring effect has been proposed. 28 In the Japan Adult Leukemia Study Group ALL 93 study, it was shown that approximately 80% and 75% of patients were alive 6 and 10 months after enrollment, respectively. 8 As 6 and 10 months were Poor-risk cytogenetics (Ph, t(4;11), t(1;19)), age435 years, WBC430 000/ mL, or failure to achieve CR after first induction course Ribera et al. 78 Ph, 11q23 rearrangements, t(1;19), age430 years, or WBC425 000/mL Rowe et al. Age435 years, time to CR44 weeks, or WBC430 000/mL (B lineage), 100 000/mL (T lineage) Pullarkat et al.
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HR: À 7, del(7p), þ 8, other 11q23(except t(4;11)), t(1;19) or t(17;19), t(5;14) or CALM-AF10 in T-cell ALL; VHR: t(4;11), t(8;14), complex (X5 unrelated clonal abnormalities), low hypodiploidy (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) , near triploidy (60-78); Ph Cornelissen et al.
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Cytogenetic abnormalities (t(9;22), t(4;11), or t(1;19)), pro-B-cell immunophenotype, WBC430 000/mL (B lineage), 100 000/mL (T lineage), or time to CR44 weeks Bassan et al. Alternative source allo-HCT for Ph( À ) ALL S Nishiwaki et al the median intervals from diagnosis to mRD and URD allo-HCTs, respectively, a crude way to apply a correction for the survival seen in the study was to lower the survival estimate at any given time point by 20% for mRD allo-HCT and 25% for URD allo-HCT. Thus, the corrected OS rates showed no statistical difference between patients who underwent mRD and URD allo-HCTs (52 ± 5% for mRD and 47 ± 4% for URD at 4 years).
Indication for URD allo-HCT for adult Ph( À ) ALL in first CR Considering recent data indicating that mRD allo-HCT in the first CR was superior to chemotherapy 22 and that the outcome of URD allo-HCT was comparable with that of mRD allo-HCT, 23 URD allo-HCT could also be indicated for adult Ph( À ) ALL in first CR. As it was concluded in a recent Japanese study that an HLA 8/8-matched URD should be prioritized over an HLA 1 antigenmismatched RD during donor selection, 29 HLA-matched URD allo-HCT may be the first choice in cases in which there is no mRD. However, as an HLA-matched URD will not always be available and slow availability would sometimes be a risk, 23 the indication for allo-HCT from other alternative sources should also be discussed to offer the best treatment choice for each patient.
UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) FOR ADULT PH( À ) ALL IN THE FIRST CR
The number of patients who underwent UCBT has recently been increasing due to the recognition that UCBT has certain advantages over URD allo-HCT, including rapid availability, low risk of infection transmission, absence of donor risk, and relatively low risk of GVHD (Table 3) . Results for the largest series of adult Ph( À ) ALL patients in Japan who underwent single UCBT (n ¼ 233) were reported. 30 Among 95 patients who underwent UCBT in first CR, OS at 4 years was 57%. The cumulative incidences of relapse and NRM were 22% and 27% at 3 years, respectively.
Comparison of URD allo-HCT and UCBT Among 529 patients who underwent transplantation in the first CR (434 URD and 95 CB cases), there were no significant differences in OS rates between patients who underwent URD allo-HCT and UCBT (64% for URD and 57% for UCBT at 4 years). Donor source was not a significant risk factor. 30 To analyze the effects of alternative donor source on various prognostic factors when a mRD was not available, the hazard ratio was examined according to the factors. UCBT would result in better survival in patients who underwent HLA-mismatched allo-HCT, whereas URD allo-HCT would be better when performed for patients X45 years, patients with normal cytogenetics, or patients transplanted from an HLA well-matched donor. A graphical presentation of the log hazard ratios is shown in Figure 1 .
Results of disease-specific analyses were also reported from Japan (URD; Ph( þ ): n ¼ 52, Ph( À ): n ¼ 170 vs UCBT; Ph( þ ): n ¼ 43, Ph( À ): n ¼ 71) 31 and Minnesota (URD: n ¼ 100 vs UCBT: n ¼ 69), 32 with data for Ph( þ ) and Ph( À ) ALL patients being analyzed together. Based on results of statistical techniques to adjust heterogeneities of the study population, it was concluded that the outcome was not significantly different between patients who underwent URD allo-HCT and UCBT.
The relationship between URD allo-HCT and UCBT would vary according to baseline diseases. A meta-analysis of seven studies comparing URD allo-HCT and UCBT for acute leukemia showed a significantly lower survival rate in patients who underwent UCBT than in patients who underwent URD allo-HCT. 33 Another study showed that HLA 0-2 antigen-mismatched UCBT resulted in a survival rate similar to that for patients who underwent single-HLA-DRB1-mismatched or other 7 of 8 URD allo-HCT. 34 However, subgroup analysis showed that survival rates were similar for patients who underwent URD allo-HCT and UCBT in ALL. 33 The same tendency was also observed in the diseasespecific analysis described above, in which UCBT resulted in comparable survival with that of URD allo-HCT in ALL but inferior survival in AML. 31 Indication for UCBT for adult Ph( À ) ALL in the first CR Considering that the outcome of UCBT was comparable to that of URD allo-HCT, UCBT could also be indicated for adult Ph( À ) ALL in the first CR. As the direction of HLA mismatch does not have a significant impact on OS after UCBT, 35 HLA 0-2 antigen-mismatched UCBT is a reasonable second alternative source. Young patients (o45 years) who do not have or need a long time to find a suitable HLA-matched URD could be good candidates for UCBT in the first CR. Alternative source allo-HCT for Ph( À ) ALL S Nishiwaki et al
ALLO-HCT FOR PH( À ) ALL BEYOND THE FIRST CR
There has been a large-scale Japanese study comparing mRD allo-HCT, URD allo-HCT, and UCBT for Ph( À ) ALL. 30 Among 300 patients who underwent transplantation in subsequent CR (89 mRD, 158 URD, and 53 UCB cases), there were no significant differences in OS rates between patients who underwent mRD allo-HCT, URD allo-HCT, and UCBT (47% for mRD, 39% for URD, and 48% for UCB at 4 years; P ¼ 0.33). Among 509 patients who underwent transplantation in non-CR (207 mRD, 217 URD, and 85 UCB cases), there were no significant differences in OS rates between patients who underwent mRD allo-HCT, URD allo-HCT, and UCBT (15% for mRD, 21% for URD, and 18% for UCB at 4 years; P ¼ 0.20). In multivariate analysis, donor source was not a significant risk factor for OS in both subsequent CR and non-CR.
The cumulative incidences of relapse and NRM were not significantly different between patients who underwent mRD allo-HCT, URD allo-HCT, and UCBT in both subsequent CR and non-CR.
It is noteworthy that some, but not all, patients with refractory disease could be rescued by UCBT as well as mRD or URD allo-HCT. 23 These patients would not have survived for long with chemotherapy alone, and therefore UCBT could be a hope of survival for patients with refractory disease who do not have a mRD or URD. It requires attention for selection biases. Younger age (o30 or o35 years) and longer duration of the first CR (X2 years) were identified as favorable prognostic factors for relapsed ALL patients in the large previous studies. 20, 21 As there are no confirmed data for relapsed patients without such favorable factors, indications for allo-HCT should be considered according to close examination of each patient status.
HAPLOIDENTICAL RELATED DONOR (HAPLO-RD)ALLO-HCT FOR ADULT ALL
The advantage of haplo-RD allo-HCT is the almost universal availability of a RD who is at least haplotype identical to the patient in need of allo-HCT (Table 4) . Such donors are usually available quickly and can serve as repeat donors in the event of engraftment failure or as donors of lymphocytes in order to convert mixed chimerism to full donor hematopoiesis or to treat disease relapse. Most published haplo-RD allo-HCT series have been small and have included patients with diverse disease and remission states at the time of allo-HCT. Variability in patient populations, conditioning regimens, and GVHD prophylaxis have made it difficult to reach a consensus about the optimal strategy for haplo-RD allo-HCT.
Most studies focused on high-risk ALL patients with data for children and adult patients being analyzed together. [36] [37] [38] For standard-risk ALL patients (87 Ph( À ) ALL patients: 82 in the first CR and 7 in the second CR), OS and relapse at 3 years were 65% and 24.3%, respectively, 39 which may be compatible with other sources. 30 In non-CR, however, as relapse rates would be extremely high (up to 62%), 36 leukemia-free survival only reached 5-7%. 37, 40 Therefore, haplo-RD allo-HCT could be considered for ALL in CR but we do not recommend it in advanced stage ALL.
Comparison of UCBT and haplo-RD allo-HCT Based on the existing data, it is not possible to make a convincing argument for the superiority of either UCBT or haplo-RD allo-HCT. 10 Although there was a randomized phase 2 trial comparing UCBT and haplo-RD allo-HCT, only six ALL patients were enrolled. 41 No consensus has been reached regarding the optimal strategy for performing haplo-RD allo-HCT. Haplo-RD allo-HCT could be a third alternative source for high-risk ALL patients in CR. The BMT Clinical Trials Network is embarking on a randomized phase 3 study comparing UCBT and haplo-RD allo-HCT. This study should provide answers to important questions regarding the risks and benefits of these two donor sources.
FUTURE CONSIDERATIONS
Techniques to improve the outcome of UCBT As delayed engraftment is one of the most common limitations of UCBT, [42] [43] [44] several strategies such as double cord units, [45] [46] [47] Age at allo-HCT, y 16< = , <45 Figure 1 . A graphical presentation of the log hazard ratios (HRs) for survival of UCBT compared with URD allo-HCT. UCBT would result in better survival in patients who underwent HLA-mismatched allo-HCT, whereas URD allo-HCT would be better when performed for patients X45 years, patients with normal cytogenetics, or patients transplanted from an HLA well-matched donor. Patients were classified at diagnosis by the Japan Adult Leukemia Study Group (JALSG) risk stratification; 8 low risk was defined as o30 years at diagnosis and WBC count of o30 000/ mL at diagnosis, high risk was defined as X30 years at diagnosis and WBC count of X30 000/mL at diagnosis, and intermediate risk was defined as other. For URD, 'well-matched' was defined as no known disparity at HLA-A, -B, -C, or -DRB1, 'partially matched' was defined as one locus disparity with their donors, and 'mismatched' was defined as X2 locus disparities. For UCB, 'well-matched' was defined as no known disparity at HLA-A, -B, -C, or -DRB1, 'partially matched' was defined as at least four locus matches, and 'mismatched' was defined as o3 locus matches. allo-HCT ¼ allogeneic hematopoietic cell transplantation; TBI ¼ total body irradiation; UCB ¼ unrelated cord blood; URD ¼ unrelated donor.
Alternative source allo-HCT for Ph( À ) ALL S Nishiwaki et al intra-BM injection, [48] [49] [50] and ex vivo expansion 51, 52 have been tried to ensure engraftment. The technical progression of UCBT could also improve the outcome of Ph( À ) ALL as well as other hematological malignancies [53] [54] [55] [56] [57] [58] [59] [60] by reducing NRM.
Indication of allo-HCT for adolescent and young adult (AYA) ALL patients The major premise to discuss alternative sources is that mRD allo-HCT shows a benefit, as noted before. It is uncertain whether AYA ALL patients could have the greatest benefit from mRD allo-HCT in the first CR. Therefore, the indication of allo-HCT from an alternative source should be considered carefully for this population.
Several studies have shown improvements in outcomes for AYA ALL patients treated with pediatric-intensified protocols instead of adult protocols. [61] [62] [63] [64] [65] As there has been no study comparing the outcomes of pediatric-intensified protocols and those of allo-HCT for AYA ALL, the indication of allo-HCT for AYA ALL is unclear. Considering the treatment strategies for pediatric ALL, allo-HCT in the first CR might not be indicated for AYA without posing risk factors to those who could receive a complete pediatric protocol. UKALL XII/ECOG 2993 reported that an MRD of X10 À 4 would be a strong adverse prognostic factor for chemotherapy. However, because MRD positivity was not associated with worse outcome in the myeloablative allograft recipients, 17 MRD assessment would become increasingly Figure 2 . An algorithm of donor selection for Ph( À ) ALL. HLA-matched URD would be the first alternative source for Ph( À ) ALL. HLA 0-2 antigen-mismatched UCBT would be the second choice, especially for young patients (o45 or 50 years) without an HLA-matched URD or patients who are in urgent need of allo-HCT. Haplo-RD allo-HCT would be considered for ALL in CR (o45 or 50 years) as a third alternative source. Allo-HCT in the first CR might not be indicated for MRD( À ) AYA who could receive a complete pediatric protocol. BSC ¼ best supportive care; CR ¼ complete remission; Haplo-RD ¼ haploidentical related donor; MAC ¼ myeloablative conditioning; MRD ¼ minimal residual disease; mRD ¼ HLA-matched related donor; non-CR ¼ non-comprete remission; op. ¼ option; PIF, primary induction failure; Ph( À ) ALL ¼ Philadelphia chromosome-negative acute lymphoblastic leukemia; RIC ¼ reduced intensity conditioning; UCB ¼ unrelated cord blood; URD ¼ unrelated donor.
Alternative source allo-HCT for Ph( À ) ALL S Nishiwaki et al essential when deciding whether to use allo-HCT in the first CR. Based on the idea of risk-adapted allo-HCT, MRD-positive patients may be candidates for allo-HCT. 66, 67 To determine whether adults receiving pediatric protocols have better outcomes will require a randomized trial.
Indication for reduced-intensity conditioning (RIC) allo-HCT for Ph( À ) ALL Most studies described above were conducted for patients with myeloablative conditioning (MAC). As the GVL effect is considered to be weak for ALL, there have been few analyses of RIC for ALL. 68 Several studies showed results of RIC for high-risk ALL, 69, 70 and the utility of RIC for ALL has been recognized. As the GVL effect on Ph( À ) ALL in the first CR was established in UKALL XII/ECOG 2993, there has been a potent rationale for evaluating RIC for Ph( À ) ALL in CR. A retrospective comparison of mRD and URD allo-HCT between 93 RIC and 1428 MAC cases from CIBMTR revealed that the statistically adjusted survival between them was comparable (3-year survival: 45% (RIC) vs 51% (MAC) in the first CR and 28% (RIC) vs 33% (MAC) in the second CR). 71 From the European Group for Blood and Marrow Transplantation, a retrospective comparison of mRD allo-HCT between RIC (n ¼ 127) and MAC (n ¼ 449) for ALL patients in CR aged X45 (including Ph( þ ) ALL patients) indicated that comparable survival rates for patients who underwent RIC and MAC suggest the utility of RIC for ALL in CR. 72 Attention should be given to the interpretation of results of these studies, as they were both statistically adjusted retrospective comparisons and, therefore, some biases based on different backgrounds might affect their outcomes. 12 Older age is known to be a strong adverse prognostic factor for ALL, and the results of conventional chemotherapy for elderly ALL patients have been dismal. 73 The utility and indication of RIC for Ph( À ) ALL, especially UCBT, 74, 75 await further studies, given that results of only a few retrospective studies on RIC for Ph( À ) ALL have been reported. Although we wait for randomized study results, RIC allo-HCT could be considered a reasonable option for Ph( À ) ALL CR patients of advanced age.
CONCLUSIONS
It is unlikely that randomized head-to-head comparisons of the three alternative sources (URD, UCB, and haplo-RD) will be performed, and therefore clinical decisions will be based on observational studies or registry retrospective comparison data. Putting emphasis on the quality and quantity of the existing data, HLA-matched URD would be the first alternative source for Ph( À ) ALL. HLA 0-2 antigen-mismatched UCBT would be the second choice, especially for young patients (o45 years) without an HLA-matched URD or patients who are in urgent need of allo-HCT. Haplo-RD allo-HCT would be considered for ALL in CR as a third alternative source. An algorithm of donor selection is shown in Figure 2 . As the three alternative sources have different characteristics, it may be difficult to make a definite hierarchy among these sources. Flexible consideration based on the latest data would be warranted according to patient status and appropriate timing of allo-HCT.
